Cyclarity Therapeutics advances series A tranche 2 funding to accelerate breakthrough cardiovascular treatment
Live Forever Club - 20-Feb-2025Statins only slow down the progression of atherosclerosis – imagine if we could actually cure it!
Matthew O’Connor
Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)
Dr. O’Connor was awarded his Master’s degree in neuroscience from Northwestern Medical in 1999 and his PhD in Biochemistry from Baylor College of Medicine in 2005. His postdoctoral research includes work at UC Berkeley on muscle stem cells and aging. He is the author of 10 published manuscripts and lead inventor on the cyclodextrin patents. He is the outgoing VP of Research at SENS Research Foundation.
Visit website: https://underdogpharma.com/team/
See also
Cyclarity Therapeutics
Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases
Details last updated 11-Mar-2020
Matthew O’Connor News
Cyclarity Therapeutics advances to clinical stage with first-in-human trial
Biospace - 08-Jan-2025A groundbreaking step toward disease-modifying treatments for cardiovascular care
Reason reports back from Rejuvenation Startup Summit 2024
Fight Aging! - 13-May-2024A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Lifespan.io speaks to Cyclarity’s CEO for an update on its novel atherosclerosis treatment
Lifespan.io (LEAF) - 19-Feb-2024The company is developing a drug called UDP-003 to treat the disease
'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases
Longevity Technology - 09-Sep-2021Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood
Matthew O’Connor is also referenced in the following:
2021 Interview With Dr Matthew OConnor
Matthew O'Connor discusses the progress of developing a new biotechnology platform
2022 Interview with Dr Matthew O’Connor
Matthew O'Connor discusses the development of new drugs based on cyclodextrins
Cyclarity Therapeutics
Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases
Interview with Dr Matthew O’Connor
Dr. Matthew O'Connor provides updates on a drug targeting the removal of 7-keto cholesterol
LessDeath
Research company that helps people join the Longevity Biotechnology industry through education and more
Longevity Hackers
Feature length documentary about longevity and radical life extension with due to be released in 2023
Longevity Summit Dublin 2022
18-Sep-2022 to 20-Sep-2022
Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers
Longevity Summit Dublin 2024
13-Jun-2024 to 16-Jun-2024
Event gathering Global Longevity and Rejuvenation community in Dublin by LEV Foundation (Dublin, Ireland)
Translating Clearance of 7-Ketocholesterol - Matthew (Oki) O’Connor at Longevity Summit Dublin 2024
Matthew O’Connor delivers a keynote on the translation of 7-Ketocholesterol clearance
Matthew O’Connor Blog Posts
10-Sep-2020
Highlights of Ending Age-Related Diseases 2020
Key points from 20 presentations from world-leading researchers
